August 17–21, 2025, Washington, DC, USA - Visit us at Booth 2230.
Read More
Email:
Phone:
Toggle navigation
Home
Services
ADC Linker Development
Chemically Cleavable Linker
Acid Cleavable Linker/Hydrazone Linker
Disulfide Linker
Enzyme Cleavable Linker
Cathepsin B Cleavable Linker/Peptide Linker
Phosphatase Cleavable Linker
Sulfatase Cleavable Linker
β-Galactosidase Cleavable Linker
β-Glucuronidases Cleavable Linker
Non-Cleavable Linker
ADC Payload Development
Biological Payload
Chemical Payload
DNA Damaging Agents
Microtubule Inhibitors
Protein Degraders
RNA Polymerase Inhibitors
Nanocarrier
Protein Toxin
ADC Manufacturing
ADC cGMP Manufacturing
ADC Fill/Finish
ADC Formulation Development
ADC Purification
ADC Linker–Payload Conjugation
Calicheamicin-Based Linker Conjugation
Deruxtecan-Based Linker Conjugation
MMAE/MMAF-Based Linker Conjugation
PBD-Based Linker Conjugation
SN-38-Based Linker Conjugation
Antibody Modification and Conjugation
Bispecific Antibody Conjugation
Carbohydrate Conjugation
Click Chemistry Conjugation
Cysteine Conjugation
Enzymatic Conjugation
Lysine Conjugation
Non-natural Amino Acids Conjugation
Site-Specific Conjugation
Thio-engineered Antibody
Tyrosine Conjugation
ADC Analysis and Characterization
In Vitro
Analysis
In Vivo
Analysis
ADC Bioanalysis
ADC Bioassay
ADME Analysis
DMPK Analysis
Drug Distribution Analysis
Drug-to-Antibody Ratio Analysis
Stability Analysis
ADC Development Platform
Antibody Fragment-Drug Conjugates (FDCs)
Bispecific Antibody-Drug Conjugates (BsADCs)
Degrader-Antibody Conjugates (DACs)
Dual-Payload Antibody–Drug Conjugates
Nanobody-Drug Conjugates (NDCs)
Scaffold-Drug Conjugates (SDCs)
Products
ADC Cytotoxin
Auristatins
Calicheamicins
Camptothecins
Daunorubicins/Doxorubicins
Duocarmycins
Maytansinoids
Piericidins
Pyrrolobenzodiazepines
Traditional Cytotoxic Agents
Other Cytotoxins
ADC Cytotoxin with Linker
ADC Linker
Cleavable Linker
Non-Cleavable Linker
Antibody-Drug Conjugates (ADCs)
Targets
AXL Targets
BCMA Targets
CD19 Targets
CD22 Targets
CD30 Targets
CD33 Targets
CD79b Targets
c-MET Targets
EGFR Targets
FOLR1 Targets
HER2 Targets
Nectin-4 Targets
ROR1 Targets
TF Targets
TROP-2 Targets
Solutions
Early Discovery
Process Development
Preclinical Studies
Resource
Frequently Asked Questions
News
Scientific Corner
Support Documents
Company
Contact Us
About Us
Careers
Inquiry
Scientific Corner
Home
Resource
Scientific Corner
Scientific Corner
Inquiry
Bioanalysis for Antibody-Drug Conjugates (ADCs)
Current Technical Development Trends in Antibody-Drug Conjugate (ADC) Drugs
Design Points and Standards for ADC Drugs
Enhance ADC Performance with Optimized Linker Development
How Endocytosis Influences the Receptor Targeting Mechanism of ADC Drugs?
How to Design A Good ADC Drug?
Key Factors in Antibody Selection for Effective ADC Drug Development
Key Points of ADC Pharmacokinetics Research
Linkers - A Crucial Factor in Antibody–Drug Conjugates
Optimize ADC Carrier Antibodies for Better Targeting and Efficacy
Overcoming ADC Conjugation Efficiency & Stability Challenges
Overview of Antibody-Drug Conjugate (ADC) Production Technologies
Review of Antibody Drug Conjugate (ADC) Purification
Strategies and Criteria for Target Selection in ADC Drug Development
*
Only for research. Not suitable for any diagnostic or therapeutic use.
Send Inquiry
-
mg
g
kg
ton
Scientific Corner
We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.
SUBMIT
Inquiry Basket
Loading ......
Delete selected
Go to checkout
